Several studies have shown that levels of MPO-DNA, markers of NETs, are elevated in patients with NASH and in mouse models of NASH (van der Windt et al., 2018; Du et al., 2022). Here, MPO is linked to metabolic dysfunction-associated steatohepatitis.